BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

In the face of defeats in three federal courts, the Trump administration has abandoned its attempt to use an administrative shortcut to impose a “most favored nation” international reference pricing scheme on Medicare Part B...
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...from BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160).Seven PD-1/PD-L1 inhibitors competed to join anti-PD-1 antibody Tyvyt sintilimab from Innovent Biologics Inc....
BioCentury | Nov 26, 2020
Finance

Pre-profit biotechs on Hong Kong exchange, STAR board could see investment influx via Stock Connect expansion

...Two —BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) and Innovent Biologics Inc....
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

...business leaders in the life sciences and healthcare industry.En route to gaining top company honors, Innovent Biologics Inc....
...won the award in the corporate category.TARGETSPD-1 (PDCD1; CD279) – Programmed cell death 1 Hongjiang Li Zai Lab Innovent Biologics I-Mab...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...reported single-agent activity for TTI-622.Additionally at SITC, Innovent Biologics Inc....
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...single agent activity for TTI-622.Additionally at SITC, Innovent Biologics Inc....
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...He was president of the Japan unit, and succeeds Ai Hua Ong. Cancer and autoimmune diseaess play Innovent Biologics Inc....
...Group Co. Ltd. hired Jian Kang as VP of IP. BC Staff Merck KGaA Johnson & Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...$520 million. That would make its offering larger than the $484.8 million IPO conducted by Innovent Biologics Inc....
Items per page:
1 - 10 of 208
BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

In the face of defeats in three federal courts, the Trump administration has abandoned its attempt to use an administrative shortcut to impose a “most favored nation” international reference pricing scheme on Medicare Part B...
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...from BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160).Seven PD-1/PD-L1 inhibitors competed to join anti-PD-1 antibody Tyvyt sintilimab from Innovent Biologics Inc....
BioCentury | Nov 26, 2020
Finance

Pre-profit biotechs on Hong Kong exchange, STAR board could see investment influx via Stock Connect expansion

...Two —BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) and Innovent Biologics Inc....
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

...business leaders in the life sciences and healthcare industry.En route to gaining top company honors, Innovent Biologics Inc....
...won the award in the corporate category.TARGETSPD-1 (PDCD1; CD279) – Programmed cell death 1 Hongjiang Li Zai Lab Innovent Biologics I-Mab...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...reported single-agent activity for TTI-622.Additionally at SITC, Innovent Biologics Inc....
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...single agent activity for TTI-622.Additionally at SITC, Innovent Biologics Inc....
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...He was president of the Japan unit, and succeeds Ai Hua Ong. Cancer and autoimmune diseaess play Innovent Biologics Inc....
...Group Co. Ltd. hired Jian Kang as VP of IP. BC Staff Merck KGaA Johnson & Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...$520 million. That would make its offering larger than the $484.8 million IPO conducted by Innovent Biologics Inc....
Items per page:
1 - 10 of 208